 SAN DIEGO, Aug. 23, 2021 PRNewswire -- Viracta Therapeutics, Inc. NASDAQ: VIRX, a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the Peoples Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd. Salubris. 